Hajos S E, Alvarez E, Pierangeli S, Margni R A, Pasqualini C D
Vet Immunol Immunopathol. 1985 Jan;8(1-2):157-69. doi: 10.1016/0165-2427(85)90119-9.
A soluble tumour-associated antigen was prepared by homogenizing AKR lymphoma cells (L15) followed by treatment with acetone and glycine-HCl buffer pH 3. It was analyzed by immunoelectrophoresis, rocket electrophoresis in the presence of Concanavalin A and SDS-PAGE. It showed rapid electrophoretic mobility, and the major component had an estimated molecular weight of 70,000 daltons. The molecular composition of the antigen included a glycoprotein. Specific antibodies against this antigen were demonstrated in BALB/c mice in which the AKR lymphoma was conditioned to grow by introducing the L15 cells into a subcutaneously implanted glass cylinder. In this model antibodies were found in both tumour-bearing (progressor) and tumour-rejecting (regressor) animals. In vivo experiments showed that pretreatment of BALB/c mice with L15 acellular extracts, 10 days before tumour challenge, led to a significant increase in allogeneic tumour growth. A rabbit anti-tumour extract serum was prepared and was rendered tumour -specific by exhaustive absorption with normal AKR serum and tissues. It shared the same epitopic specificity with tumour progressor or regressor mouse sera since indirect immunofluorescence using L15 cells could be reciprocally inhibited.
通过将AKR淋巴瘤细胞（L15）匀浆，然后用丙酮和pH 3的甘氨酸 - HCl缓冲液处理，制备了一种可溶性肿瘤相关抗原。通过免疫电泳、在伴刀豆球蛋白A存在下的火箭电泳和SDS - 聚丙烯酰胺凝胶电泳对其进行了分析。它显示出快速的电泳迁移率，主要成分的估计分子量为70,000道尔顿。该抗原的分子组成包括一种糖蛋白。在将L15细胞皮下植入玻璃圆筒中以使AKR淋巴瘤能够生长的BALB/c小鼠中，证明了针对该抗原的特异性抗体。在这个模型中，在荷瘤（进展型）和肿瘤排斥（消退型）动物中都发现了抗体。体内实验表明，在肿瘤攻击前10天用L15无细胞提取物预处理BALB/c小鼠，会导致同种异体肿瘤生长显著增加。制备了兔抗肿瘤提取物血清，并通过用正常AKR血清和组织进行彻底吸收使其具有肿瘤特异性。由于使用L15细胞的间接免疫荧光可以相互抑制，它与肿瘤进展型或消退型小鼠血清具有相同的表位特异性。
